Abstract
Angiotensin-receptor blockers (ARBs) are recommended for patients with heart failure (HF) and left ventricular systolic dysfunction who do not tolerate angiotensin-converting enzyme inhibitors. Although the recommendation assumes a class effect of ARBs, some observational data suggest that, compared with other ARBs, losartan is associated with higher mortality in HF patients. In an analysis of …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
